NCT05999812View on ClinicalTrials.gov

Clinical Trial of All-trans-retinoic Acid, Bevacizumab and Atezolizumab in Colorectal Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

December 19, 2023

Primary Completion Date

October 1, 2026

Study Completion Date

October 1, 2028

Conditions
Colorectal Cancer
Interventions
DRUG

all trans Retinoic Acid

ATRA orally 45 mg/m2 QD in 2 divided doses days 1-7, repeat every 14 days

DRUG

Atezolizumab

Atezolizumab IV D1, 840 mg every 14 days

DRUG

Bevacizumab

Bevacizumab IV D1, 10 mg/kg every 14 days

Trial Locations (1)

75390

University of Texas Southwestern Medical Center, Dallas

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

University of Texas Southwestern Medical Center

OTHER